SUVEN LIFE SCIENCES LIMITED CTAD-2022 is a meeting focused entirely on Alzheimer's Disease Therapeutic Trials with key leaders in Alzheimer Disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the Alzheimer's disease.
About
Suven is a bio-pharmaceutical company, focused on discovering and developing novel pharmaceutical products, for central nervous system ('CNS') disorders using G ProteinCoupled Receptor targets. Our focus has been on discovery and development of innovative molecules targeting diseases and areas, which has undiscovered medical treatment opportunities. Our Company singularly focuses on development of 'New Chemical Entities' ('NCEs') molecules for CNS diseases such as Alzheimer's, various forms of Dementia, Narcolepsy, Major Depressive Disorder ('MDD'), Attention Deficient Hyperactivity Disorder ('ADHD'), Huntington's disease, Parkinson, Bipolar disorder and different forms of neuropsychiatry disorders, gastro and pain. Suven has 7 clinical stage compounds, including this Phase 3 Masupirdine (SUVN-502) for treatment of agitation in patients with dementia of the Alzheimer's type, ongoing Phase-2 Samelisant (SUVN-G3031) for sleep disorders (Narcolepsy), Phase 2 ready Ropanicant (SUVN-911) for Major Depressive Disorder (MDD) and Phase 2 ready Usmarapride (SUVN-D4010) for cognitive disorders. In addition to clinical candidates, Suven has 8 molecules in development pipeline.
About Masupirdine
Masupirdine, a serotonin-6 (5-HT6) receptor antagonist is being developed for the treatment of agitation in patients with dementia of the Alzheimer's type. In animal models, masupirdine showed significant reduction in agitation like behaviors and modulated the neurotransmitters implicated in modulation of mood and behavior. Post-hoc analyses of the Phase-2 study (NCT02580305) evaluating masupirdine for the treatment of cognitive deficits in patients with moderate Alzheimer's disease (AD) suggested potential beneficial effects on agitation/aggression.
Contact:
Tel: 91 40 2354 1142
Fax: 91 40 2354 1152
Email: info@suven.com website: www.suven.com
(C) 2022 Electronic News Publishing, source
